Urelumab Combo Leads to Improved Pathologic Response in Resectable PDAC
Improved antitumor activity of the triplet combination of urelumab, a GVAX vaccine, and nivolumab (Opdivo) was observed in patients with resectable pancreatic ductal adenocarcinoma (PDAC), according to findings from a 3-arm phase 1/2 trial (NCT02451982) that were presented during the 35th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2020). Specifically, a 30% pathologic response rate and a mild toxicity pro-file for the triplet was also observed in the trial.
The 3 pathologic responses were moderate per the College of American Pathologists grade 2 criteria. Nine patients remain disease free after a median follow-up of 12 months. Read more . . .